It would be fair to say biotech has had an interesting time of it over the course of the past 15 months. Except, of course, that biotech always has an interesting time of it. The go big or go home sector of the market attracts speculators, scientists, and unsavory characters, but also attracts people hoping for critical improvements to their healthcare options.
With a lot of sentiment and sometimes too little information, it can be hard to find an edge. Throw in the political questions stemming from stories like Valeant (NYSE:VRX), Sarepta (NASDAQ:SRPT), and Mylan (NASDAQ:MYL), and the interesting times don’t appear likely to go away.
With an assist from SA Managing Editor (and CFA) Mike Taylor, we asked a few authors who focus on the biotech sector to tell us which way they think the winds might blow.
Bret Jensen, author of The Biotech Forum ONeil Trader, author of Growth Stock Forum Bhavneesh Sharma, author of Vasuda Healthcare A nalytics Chris Lau, author of Value Stocks for DIY Investors Alexander J. Poulos, author of Undervalued Gems Wall Street Titan, author of Stem Cell Sector News and Analysis
Seeking Alpha: Investors are aware of headline political risk this year, but there’s also some regulator level confusion. On one hand, we have a recent approval decision on a six-figure drug from Sarepta with controversy over efficacy, to put it mildly. On the other hand, there’s uproar over the EpiPen, which some argue is expensive but at least is acknowledged to work. How are you evaluating the FDA’s and regulators’ posture relative to industry?
Best Biotech Stocks To Invest In Right Now: Cheniere Energy, Inc.(LNG)
- [By Brian Feroldi, Chuck Saletta, Tyler Crowe, Jason Hall, and Jordan Wathen]
With that in mind, we asked a team of Fools each to highlight a stock that a billionaire investor has been selling recently. Read on to see why they chose Cheniere Energy (NYSEMKT:LNG), Activision Blizzard (NASDAQ:ATVI), Suncor Energy (NYSE:SU), MGIC Investment Corporation (NYSE:MTG), and Extended Stay America (NYSE:STAY).
- [By Craig Jones]
Pete Najarian noticed that somebody bought 17,000 contracts of the July 55 calls in Cheniere Energy, Inc.(NYSE: LNG) for $0.60. He followed the trade and he is planning to hold it until expiration. The trade breaks even at $55.60 or 9.90 percent higher.
- [By Manikandan Raman]
Bays said the momentum would boost fortunes for projects like Cheniere Energy, Inc. (NYSE: LNG)’s Corpus Christi, Liquefied Natural Gas Ltd (ASX:LNG)’s Magnolia, and Tellurian Inc (NASDAQ: TELL)’s Driftwood LNG project, among others.
Best Biotech Stocks To Invest In Right Now: TheStreet, Inc.(TST)
- [By Steven Goldberg]
Launched in August 2001, Action Alerts PLUS Portfolio has been a centerpiece of the financial advice offered by TheStreet.com. The website belongs to TheStreet, Inc. (TST), a publicly traded company that Cramer co-founded in 1996. PLUS Portfolio subscribers, who pay $15 a month, always get the recommendations before Cramer buys them for the portfolio, the Wharton paper reports. Likewise, subscribers get Cramers picks before he airs them on Mad Money.
Best Biotech Stocks To Invest In Right Now: Cracker Barrel Old Country Store Inc.(CBRL)
- [By Monica Gerson]
Cracker Barrel Old Country Store, Inc. (NASDAQ: CBRL) is projected to report its quarterly earnings at $1.80 per share on revenue of $705.65 million.
- [By Monica Gerson]
Analysts are expecting Cracker Barrel Old Country Store, Inc. (NASDAQ: CBRL) to have earned $1.80 per share on revenue of $705.65 million in the latest quarter. Cracker Barrel shares gained 0.67 percent to $152.50 in after-hours trading.
- [By Jake L’Ecuyer]
Cracker Barrel Old Country Store (NASDAQ: CBRL) shares tumbled 2.50 percent to $104.32 after the company reported a 1.1% drop in its fiscal fourth-quarter earnings and issued a downbeat Q1 forecast.
- [By Shauna O’Brien]
Cracker Barrel Old Country Store, Inc. (CBRL) shares dropped over 4% on Wednesday morning after the company reported lower fourth quarter earnings and a weak outlook for its first quarter.
The Lebanon, TN-based company reported fourth quarter earnings of $34.3 million, or $1.43 per share, down slightly from $34.7 million, or $1.47 per share, a year ago. On average, analysts expected to see earnings of $1.35 per share.
Total revenue fell to $646.1 million from $700.01 million last year. Analysts expected to see revenue of $668.68 million.
Cracker Barrel President and CEO Sandra Cochran commented: “The fourth quarter of fiscal 2013 represents the seventh consecutive quarter of year-over-year improvement in comparable store traffic, restaurant sales, and retail sales. The financial results of the fourth quarter and full year reflect the effective execution of our strategic plan. As we begin our 2014 fiscal year, we are poised to capitalize on the achievements of fiscal 2013.”
For FY2013, CBRL’s earnings rose 14% to $117.27 million, while EPS rose to $4.90 per share. On an adjusted basis, earnings were $4.97 per share, up 15% from the year prior. Total revenue for the year was $2.64 billion, up 3% from a year ago.
Looking forward, the company expects to see first quarter earnings between $1.05 and $1.15 per share. This estimate would fall significantly below the average analyst estimate of $1.32 per share.
For FY2014, the company expects EPS in the range of $5.60 to $5.80 and revenue between $2.7 billion and $2.75 billion. Analysts expect to see earnings of $5.69 per share and $2.74 billion in revenue.
Cracker Barrel shares were down $4.70, or 4.39%, during Wednesday morning trading. The stock is up 59% YTD.